Stock Events

Stock Events

Oncopeptides AB 

SEK1.4600
29
-SEK0.05-3.18% Monday 16:24

Statistics

Day High
1.52
Day Low
1.416
52W High
2
52W Low
1.416
Volume
679,031
Avg. Volume
1,331,984
Mkt Cap
308.45M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-0.03
-0.03
-0.02
-0.02
Expected EPS
N/A
Actual EPS
N/A

Financials

-350.94%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
194.79MRevenue
-683.58MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap128.81B
Bristol-Myers Squibb competes in the oncology space with a broad portfolio of drugs that could be used in similar indications as Oncopeptides' therapies.
Johnson & Johnson
JNJ
Mkt Cap650.65B
Johnson & Johnson, through its subsidiary Janssen, develops multiple myeloma treatments that directly compete with Oncopeptides' products.
AMGEN
AMGN
Mkt Cap208.49B
Amgen has a strong presence in the oncology market, including treatments for multiple myeloma, making it a direct competitor.
Gilead Sciences
GILD
Mkt Cap186.13B
Gilead Sciences, with its acquisition of Kite Pharma, has expanded its oncology portfolio, including therapies that could compete in the same space as Oncopeptides.
Novartis
NVS
Mkt Cap266.8B
Novartis offers several cancer treatments, including therapies for multiple myeloma, positioning it as a competitor.
Pfizer
PFE
Mkt Cap157.65B
Pfizer has a growing oncology division with treatments that could compete against Oncopeptides' pipeline.
Abbvie
ABBV
Mkt Cap466.45B
AbbVie, with its broad oncology portfolio, including therapies for hematologic cancers, competes in the same market as Oncopeptides.
Merck
MRK
Mkt Cap362.35B
Merck & Co.'s strong oncology pipeline, including treatments for various cancers, makes it a competitor.
Takeda Pharmaceutical
TAK
Mkt Cap60.39B
Takeda Pharmaceutical, with its acquisition of Shire, has strengthened its position in the oncology market, including treatments for multiple myeloma, competing with Oncopeptides.

About

Oncopeptides AB (publ) is a biotechnology firm dedicated to developing medical therapies for cancer, serving markets across the United States, Europe, and worldwide. Its foremost experimental compound, melflufen, is a distinct peptide-drug conjugate engineered to address multiple myeloma that has relapsed or become resistant to prior treatments in adult individuals. Founded in 2000, Oncopeptides AB (publ) conducts its main business from Stockholm, Sweden.
Show more...
CEO
Sofia Heigis
Employees
69
Country
Sweden
ISIN
SE0027999608

Listings

MU
DE
OND.MU
STU
DE
OND.STU
ST
SE
ONCO.ST
LSE
GB
0RN4.LSE

0 Comments

Share your thoughts

FAQ

What is Oncopeptides AB stock price today?▼
The current price of ONCO-BTA.ST is SEK1.46 SEK — it has decreased by -3.18% in the past 24 hours. Watch Oncopeptides AB stock price performance more closely on the chart.
What is Oncopeptides AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Stockholm Exchange exchange Oncopeptides AB stocks are traded under the ticker ONCO-BTA.ST.
Is Oncopeptides AB stock price growing?▼
ONCO-BTA.ST stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Oncopeptides AB has showed a -69.26% decrease.
What is Oncopeptides AB market cap?▼
Today Oncopeptides AB has the market capitalization of 308.45M
What is Oncopeptides AB revenue for the last year?▼
Oncopeptides AB revenue for the last year amounts to 194.79M SEK.
What is Oncopeptides AB net income for the last year?▼
ONCO-BTA.ST net income for the last year is -683.58M SEK.
How many employees does Oncopeptides AB have?▼
As of September 23, 2026, the company has 69 employees.
In which sector is Oncopeptides AB located?▼
Oncopeptides AB operates in the Health & Wellness sector.
When did Oncopeptides AB complete a stock split?▼
Oncopeptides AB has not had any recent stock splits.
Where is Oncopeptides AB headquartered?▼
Oncopeptides AB is headquartered in Stockholm, Sweden.